Publications

Scholarly Journals--Published

  • Hsueh C T, Selim J H, & Tsai J Y. (2016). Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World Journal of Gastroenterology, 22(31), 7080-7090. Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma. (08/2016) (link)
  • Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016;22(31):7080-7090. (2016)
  • Kuo C C, Chen J J, Tsai J Y, & Hsueh C T. Effects of Chinese herbal medicine in combination with mitomycin C on gastric cancer cells. Biomark Res 2014; 2(1), 26. (2014) (link)
  • Tsai JY, Ianniti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K, Safran H. Phase I study of docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer. American Journal of Clinical Oncology 2005;28(4):329-333. (2005 - Present)
  • Tsai JY, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Stuart K, Kennedy T, Safran H. Phase I/II study of docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer. Proc Am Soc Clin Oncol 2004;23:321(Abstract 4035). (2004 - Present)
  • Safran H, Iannitti D, Ramanathan R, Schwartz J, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes M, Maia C, Pasquariello T, King T, Tsai JY, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation 2004;22(5): 706-712. (2004 - Present)
  • Safran H, Dipetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Constantino M, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Ng T, Reeder L, Adrian A, Kennedy T, Bapsi C, Choy H. Herceptin, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Investigation 2004; 22(5): 670-677. (2004 - Present)
  • Tsai JY, Nadeem A, Safran H. Chemotherapy for pancreatic cancer. Medicine & Health, Rhode Island 2004; 87(5): 132-134. (2004 - Present)
  • Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Asiner S, Hameed M. Her-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Investigation 2004; 22(1): 16-24. (2004 - Present)
  • Tsai JY, Constantinou M, Khurshid H, Moore T, Rathore R, Maia C, Hughes M, Harrington D, Kennedy T, Safran H. A phase I study of capecitabine, docetaxel, and carboplatin in metastatic esophagogastric cancer. Proc Am Soc Clin Oncol 2003; 22:318 (Abstract 1276). (2003 - Present)
  • Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Investigation 2003; 21(6): 887-896. (2003 - Present)
  • Tsai JY, Iannitti D, Safran H. Combined modality therapy for pancreatic cancer. Seminars in Oncology 2003; 30(4 Suppl 9): 71-79. (2003 - Present)
  • Tsai JY, Safran H. Status of treatment for advanced gastric carcinoma. Current Oncology Reports 2003; 5(3): 210-218. (2003 - Present)
  • Barbashina V, Benevenia J, Aviv H, Tsai J, Patterson F, Aisner S, Cohen S, Fernandes H, Skurnick J, Hameed M. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases. Journal of Cancer Research and Clinical Oncology 2002; 128(11): 610-616. (2002 - Present)
  • Tsai JY, Aviv H, Benevenia J, Patterson F, Aisner S, Pliner L, Hameed M. Prognostic factors in osteosarcoma - role of Her-2/neu and p53: an immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) analysis. Proc Am Soc Clin Oncol 2001; 20: 295b (Abstract 2933) (2001 - Present)
  • Tsai JY, Ling M, Chang VT, Hwang SS, Kasimis BS. Hemorrhagic ascites: an unusual manifestation of prostate carcinoma. The American Journal of Medicine 2001; 111(3): 245-6. (2001 - Present)